Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast cancers

Journal of Immunology

Volumn 177, Issue 4, 2006, Pages 2717-2727

  Janjic, Bratislav ^a   Andrade, Pedro ^a   Wang, Xiao Fei ^c   Fourcade, Julien ^a   Almunia, Christine ^c   Kudela, Pavol ^a,b   Brufsky, Adam ^a   Jacobs, Samuel ^a   Friedland, David ^a   Stoller, Ronald ^a   Gillet, Daniel ^c   Herberman, Ronald B ^a   Kirkwood, John M ^a   Maillere, Bernard ^c   Zarour, Hassane M ^a,d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b CANCER RESEARCH INSTITUTE   (Slovakia)

^c CEA SACLAY   (France)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CANCER VACCINE; CD4 ANTIGEN; EPITOPE; GAMMA INTERFERON; GENE PRODUCT; HLA DR ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; PACLITAXEL; PROTEIN; PROTEIN TRAG 3; T LYMPHOCYTE RECEPTOR BETA CHAIN; TRAG 3 PROTEIN[34-48]; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANIMAL CELL; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CD4+ T LYMPHOCYTE; CELL CLONE; CONTROLLED STUDY; DENDRITIC CELL; GENE; GENETIC ANALYSIS; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; LUNG CANCER; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR GENE; TRAG 3 GENE;

EID: 33746862162     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.4.2717     Document Type: Article

References (53)

1. + T lymphocytes. Nature 421: 852-856.
2. Sun, J. C., and M. J. Bevan. 2003. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300: 339-342.
3. Rocha, B. 2002. Requirements for memory maintenance. Nat. Immunol. 3: 209-210.
4. + T-cell responses. Curr. Opin. Immunol. 16: 259-263.
5. Wang, R. F., X. Wang, A. C. Atwood, S. L. Topalian, and S. A. Rosenberg. 1999. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 284: 1351-1354.
6. + T cells. J. Exp. Med. 189: 1659-1668.
7. + T cells. Proc. Natl. Acad. Sci. USA 97: 400-405.
8. + T cells. Cancer Res. 62: 213-218.
9. + T cells. Cancer Res. 60: 4946-4952.
10. + T cells. Cancer Res. 63: 6506-6515.
11. + T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc. Natl. Acad. Sci. USA 98: 3964-3969.
12. + T cells from patients with NY-ESO-1-expressing melanoma. J. Immunol. 174: 1751-1759.
13. + T lymphocytes of patients with NY-ESO-1-expressing melanoma. J. Exp. Med. 191: 625-630.
14. + T lymphocytes. J. Exp. Med. 189: 767-778.
15. + cytolytic T lymphocytes. Cancer Res. 60: 6272-6275.
16. Jassim, A., W. Ollier, A. Payne, A. Biro, R. T. Oliver, and H. Festenstein. 1989. Analysis of HLA antigens on germ cells in human semen. Eur. J. Immunol. 19: 1215-1220.
17. + T cell responses to SSX-4 in melanoma patients. J. Immunol. 174: 5092-5099.
18. + T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc. Natl. Acad. Sci. USA 100: 8862-8867.
19. Jager, E., Y. Nagata, S. Gnjatic, H. Wada, E. Stockert, J. Karbach, P. R. Dunbar, S. Y. Lee, A. Jungbluth, D. Jager, et al. 2000. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc. Natl. Acad. Sci. USA 97: 4760-4765.
20. Feller, A. J., Z. Duan, R. Penson, H. C. Toh, and M. V. Seiden. 2000. TRAG-3, a novel cancer/testis antigen, is overexpressed in the majority of melanoma cell lines and malignant melanoma. Anticancer Res. 20: 4147-4151.
21. Wu, Y. Z., T. T. Zhao, B. Ni, L. Y. Zou, H. L. Liu, and B. Zhu. 2003. Expression of TRAG-3 in breast cancer. Int. J. Cancer 107: 167-168.
22. Chen, Z., B. Zhu, and Y. Wu. 2002. Expression of TRAG-3 antigen in non-small-cell lung carcinomas. Lung Cancer 38: 101-102.
23. Duan, Z., A. J. Feller, H. C. Toh, T. Makastorsis, and M. V. Seiden. 1999. TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line. Gene 229: 75-81.
24. Zhu, B., Z. Chen, X. Cheng, and Y. Wu. 2002. Induction of TRAG-3 expression in A549 lung adenocarcinoma cell line by 5-aza-2′- deoxyazacytidine. Lung Cancer 38: 321-322.
25. Meier, A., S. Reker, I. M. Svane, L. Holten-Andersen, J. C. Becker, I. Sondergaard, M. H. Andersen, and P. Thor Straten. 2005. Spontaneous T-cell responses against peptides derived from the taxol resistance-associated gene-3 (TRAG-3) protein in cancer patients. Cancer Immunol. Immunother. 54: 219-228.
26. Zhu, B., Z. Chen, X. Cheng, Z. Lin, J. Guo, Z. Jia, L. Zou, Z. Wang, Y. Hu, D. Wang, and Y. Wu. 2003. Identification of HLA-A*0201-restricted cytotoxic T lymphocyte epitope from TRAG-3 antigen. Clin. Cancer Res. 9: 1850-1857.
27. Turvy, D. N., and J. S. Blum. 1998. Detection of biotinylated cell surface receptors and MHC molecules in a capture ELISA: a rapid assay to measure endocytosis. J. Immunol. Methods 212: 9-18.
28. Watson, A. J., R. DeMars, I. S. Trowbridge, and F. H. Bach. 1983. Detection of a novel human class II HLA antigen. Nature 304: 358-361.
29. Zarour, H., C. De Smet, F. Lehmann, M. Marchand, B. Lethe, P. Romero, T. Boon, and J. C. Renauld. 1996. The majority of autologous cytolytic T-lymphocyte clones derived from peripheral blood lymphocytes of a melanoma patient recognize an antigenic peptide derived from gene Pmel17/gp100. J. Invest. Dermatol. 107: 63-67.
30. Texier, C., S. Pouvelle, M. Busson, M. Herve, D. Charron, A. Menez, and B. Maillere. 2000. HLA-DR restricted peptide candidates for bee venom immunotherapy. J. Immunol. 164: 3177-3184.
31. Texier, C., S. Pouvelle-Moratille, M. Busson, D. Charron, A. Menez, and B. Maillere. 2001. Complementarity and redundancy of the binding specificity of HLA-DRB1, -DRB3, -DRB4 and -DRB5 molecules. Eur. J. Immunol. 31: 1837-1846.
32. Castelli, F. A., C. Buhot, A. Sanson, H. Zarour, S. Pouvelle-Moratille, C. Nonn, H. Gahery-Segard, J. G. Guillet, A. Menez, B. Georges, and B. Maillere. 2002. HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity. J. Immunol. 169: 6928-6934.
33. + T cell responses against viral and tumor antigens using T cells as novel target APC. J. Immunol. Methods 278: 57-66.
34. Stockert, E., E. Jager, Y. T. Chen, M. J. Scanlan, I. Gout, J. Karbach, M. Arand, A. Knuth, and L. J. Old. 1998. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Med. 187: 1349-1354.
35. Genevee, C., A. Diu, J. Nierat, A. Caignard, P. Y. Dietrich, L. Ferradini, S. Roman-Roman, F. Triebel, and T. Hercend. 1992. An experimentally validated panel of subfamily-specific oligonucleotide primers (Vα1-w29/Vβ1-w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction. Eur. J. Immunol. 22: 1261-1269.
36. Southwood, S., J. Sidney, A. Kondo, M. F. del Guercio, E. Appella, S. Hoffman, R. T. Kubo, R. W. Chesnut, H. M. Grey, and A. Sette. 1998. Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol. 160: 3363-3373.
37. Sercarz, E. E., P. V. Lehmann, A. Ametani, G. Benichou, A. Miller, and K. Moudgil. 1993. Dominance and crypticity of T cell antigenic determinants. Annu. Rev. Immunol. 11: 729-766.
38. Sant, A. J., F. A. Chaves, S. A. Jenks, K. A. Richards, P. Menges, J. M. Weaver, and C. A. Lazarski. 2005. The relationship between immunodominance, DM editing, and the kinetic stability of MHC class II:peptide complexes. Immunol. Rev. 207: 261-278.
39. Rosenthal, A. S. 1978. Determinant selection and macrophage function in genetic control of the immune response. Immunol. Rev. 40: 136-152.
40. Sinigaglia, F.. M. Guttinger, J. Kilgus, D. M. Doran, H. Matile, H. Etlinger, A. Trzeciak, D. Gillessen, and J. R. Pink. 1988. A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules. Nature 336: 778-780.
41. Panina-Bordignon, P., A. Tan, A. Termijtelen, S. Demotz, G. Corradin, and A. Lanzavecchia. 1989. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. 19: 2237-2242.
42. Ferrari, C., A. Bertoletti, A. Penna, A. Cavalli, A. Valli, G. Missale, M. Pilli, P. Fowler, T. Giuberti, F. V. Chisari, et al. 1991. Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J. Clin. Invest. 88: 214-222.
43. Valli, A., A. Sette, L. Kappos, C. Oseroff, J. Sidney, G. Miescher, M. Hochberger, E. D. Albert, and L. Adorini. 1993. Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J. Clin. Invest. 91: 616-628.
44. + T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J. Virol. 71: 6011-6019.
45. Tangri, S., B. R. Mothe, J. Eisenbraun, J. Sidney, S. Southwood, K. Briggs, J. Zinckgraf, P. Bilsel, M. Newman, R. Chesnut, C. Licalsi, and A. Sette. 2005. Rationally engineered therapeutic proteins with reduced immunogenicity. J. Immunol. 174: 3187-3196.
46. + T cell responses in cancer patients. Clin. Immunol. 118: 188-194.
47. + T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients. Cancer Res. 63: 5601-5606.
48. + T cell responses in patients with hepatocellular carcinoma. J. Immunol. 174: 1709-1716.
49. + T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res. 60: 4499-4506.
50. Busser, B. W., M. P. Cancro, and T. M. Laufer. 2004. An increased frequency of autoantibody-inducing CD4+ T cells in pre-diseased lupus-prone mice. Int. Immunol. 16: 1001-1007.
51. Peng, S. L., S. Fatenejad, and J. Craft. 1996. Induction of nonpathologic, humoral autoimmunity in lupus-prone mice by a class II-restricted, transgenic αβ cell: separation of autoantigen-specific and -nonspecific help. J. Immunol. 157: 5225-5230.
52. Jahn-Schmid, B., P. Kelemen, M. Himly, B. Bohle, G. Fischer, F. Ferreira, and C. Ebner. 2002. The T cell response to Art v 1, the major mugwort pollen allergen, is dominated by one epitope. J. Immunol. 169: 6005-6011.
53. + patients with renal cell carcinoma or melanoma. J. Exp. Med. 196: 619-628.